Gene therapy study for nerve pain from small fiber neuropathy
Part of Brain & nervous system clinical trials.
This trial tests a new gene therapy called ST-503 for people with long-lasting nerve pain from small fiber neuropathy that hasn't improved with standard treatments. The study will check if the treatment is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small fiber neuropathy (SFN) with chronic nerve pain.
- Your pain has not responded to at least 2 of the 3 main types of standard pain medications for at least 6 months.
- You do not have antibodies against the AAV9 virus used in this gene therapy (a blood test will check this).
- You are not currently using opioid painkillers unless you have been on a stable dose for at least 3 months and won't need to increase it.
- You have no history of alcohol or drug abuse in the last 2 years, and you do not use cannabis products.
- You have no active infections, serious liver problems, or a history of cancer (except minor skin cancer or fully treated early breast cancer) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of spinal cord stimulation for people with long-term nerve pain that hasn't improved with other treatments. The goal is to see if this special stimulation pattern can reduce pain better than standard care.
This trial tests how well two types of peripheral nerve stimulation (PNS) devices relieve chronic pain caused by a single nerve injury. It looks for people who already have a referral for PNS therapy as part of their usual care and who have gotten at least 50% relief from a diagnostic nerve block.
This trial tests whether stimulating two brain networks with implanted electrodes can relieve chronic nerve pain that hasn't responded to other treatments. It is for people with severe pain lasting more than six months.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
This study looks at whether people with fibromyalgia or long-term chronic pain have damage to the small nerve fibers in their skin. Understanding this could help develop better treatments.
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
Hear when a new Chronic Neuropathic Pain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.